Life Sciences

Juno Therapeutics appoints Sunil Agarwal as President of R&D

April 21, 2017

Juno Therapeutics, Inc., a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced it has appointed Sunil Agarwal, M.D., as President of Research and Development. With Dr. Agarwal’s appointment, Juno will bring Research and Development under one leader responsible for the..

EU crushes U.K. hopes of retaining EMA after Brexit

April 21, 2017

The European Commission has again sought to extinguish the United Kingdom’s lingering hopes of keeping the European Medicines Agency (EMA) in London after Brexit. Lead Brexiteer David Davis became the latest politician to claim London could retain the regulator earlier this week, only for a..

Report: Price hikes are still driving pharma’s earnings growth

April 20, 2017

Defying pressure from politicians and the public, pharma largely continued its price-hiking ways in 2016, with the corresponding sales windfall equal to 100% of the industry’s EPS growth for the year. That’s one conclusion in a new report from Credit Suisse, which found that net..

Japan’s Sawai buys U.S. firm Upsher-Smith’s generic drugs unit

April 20, 2017

Japan’s Sawai Pharmaceutical Co Ltd is buying the generic drug business of U.S. drug maker Upsher-Smith Laboratories Inc for $1.05 billion, marking the Osaka-based generic drugmaker’s first overseas acquisition. Sawai said on Thursday it is acquiring the business of the Minnesota-based company from the founding..

The world’s most pricey drugs

April 20, 2017

When Biogen announced the price on its new rare disease drug Spinraza—$750,000 the first year and $375,000 after that—critics popped up immediately. Biogen and its partner Ionis saw their shares drop. Biogen tried to explain. It had “carefully considered” the price, spokesman Matt Fearer told..

China pharma poised for explosive growth, Novartis CEO says

April 19, 2017

As drugmakers face growth challenges in the U.S. and other developed countries, China is looking more enticing to one CEO. Novartis chief Joe Jimenez thinks the market is set for a boom period as the industry launches a wave of new meds in the country…

Alpine bags Nivalis, making Gold a public biotech CEO again

April 19, 2017

Alpine Immune Sciences is set to merge with Nivalis Therapeutics and snag itself a stock listing in the process. The agreement puts Mitch Gold back at the helm of a public biotech for the first time since the downfall of Dendreon precipitated his departure from..

Cardinal Health buys Medtronic units for $6B

April 19, 2017

Cardinal Health said Tuesday it had agreed to acquire Medtronic’s medical supplies units for $6.1 billion but shares of the medical device giant plunged on a forecast for fiscal 2017 earnings that was at the low end of its earlier guidance. Medtronic’s patient care, deep..

Vertex CEO Leiden’s pay plummets 40% amid revised exec pay plan

April 19, 2017

In 2014, Vertex CEO Jeff Leiden raised eyebrows all over Wall Street when he took home a $45.8 million pay package—a remarkable sum for a biotech company just starting to make its mark in the cystic fibrosis market. Vertex responded to the backlash: Last February..

CRO Chiltern, valued at $1.3B, could be up for sale: Reuters

April 18, 2017

U.K.-based CRO Chiltern has put itself up for sale as it continues the bullish M&A run for contract research groups that has seen a host of deals, JVs and mergers over the last 2 years. This is according to Reuters, citing anonymous “people familiar with..